News

  • by Marissa Plescia
    A new report from Trilliant Health finds behavioral health demand has surged since 2018, but workforce shortages and access barriers continue to limit care. The post Behavioral Health Demand Has Increased by 62% Since 2018. What the Industry Needs to Know appeared first on MedCity News.
  • by Frank Vinluan
    Kailera Therapeutics’ IPO proceeds will support global clinical trials for its obesity drug candidates. Meanwhile, proteomics company Alamar Biosciences upsized its own IPO while clinical-stage biotechs Seaport Therapeutics and Hemab Therapeutics joined the IPO queue. The post Kailera’s Upsized IPO Brings In $625M for Pipeline of Injectable & Oral Obesity Drugs appeared first on MedCity […]
  • by Guillaume Castel
    These day-to-day issues are directly responsible for rising rates of clinician burnout, exacerbating the serious shortage of doctors and nurses facing the US in the next decade. The post Your Doctors and Nurses Are Burned Out. Here’s What They Need appeared first on MedCity News.
  • by Héctor Upegui
    The future of social security depends on the strength of our collaboration and our unwavering commitment to the people we serve. The challenges are significant, but so are the opportunities for innovation. The post Strengthening Social Security in a Changing World appeared first on MedCity News.
  • by Marissa Plescia
    Wisp partnered with Visby Medical to expand access to Visby’s at-home sexually transmitted infection test and provide follow-up treatment through Wisp’s telehealth platform. The post Wisp, Visby Partner to Expand Access to At-Home STI Test appeared first on MedCity News.
  • by Katie Adams
    CMS is rolling out its health tech ecosystem initiative with a new Medicare app library that functions like a healthcare “App Store,” aiming to make patient data more portable and accessible across vetted digital health apps. The post CMS’ New ‘App Store’ Is Trying to Turn Interoperability Into a Digital Health Distribution System appeared first […]
  • by Frank Vinluan
    The fatty liver disease MASH is one of the metabolic disorders that Nula Therapeutics is pursuing. The startup’s small molecules are intended to restore the integrity of the nuclear envelope, a cellular membrane whose dysfunction can contribute to metabolic disease. The post Startup Nula Emerges to Advance a New Class of Medicines for Metabolic Disease […]
  • by Maria-Magdalena Patru
    Innovations in biomarker science, particularly in cerebrospinal fluid (CSF) and blood, are expanding Alzheimer’s testing beyond specialty care. The post The Key Biomarkers Changing How and When We Diagnose Alzheimer’s Disease appeared first on MedCity News.
  • by Patrick Doolittle
    The difference between that last era and this one isn’t incremental. It’s categorical. Artificial intelligence isn’t optimizing the old system. It’s making the old system economically indefensible. The post The End of Incrementalism: Why Healthcare Innovation is Finally Reshaping the Model appeared first on MedCity News.
  • by Marissa Plescia
    Rep. Greg Murphy introduced a bill that would require out-of-pocket prescription drug spending to count toward patients’ deductibles and out-of-pocket maximums regardless of where the drugs are purchased. The post New Bill Seeks to Lower Out-of-Pocket Drug Costs appeared first on MedCity News.
  • by Katie Adams
    Innovaccer is committing $250 million to expand its AI agent platform, which automates workflows across areas like prior authorization, revenue cycle management and population health. The move comes amid an ongoing debate over whether administrative AI tools can ultimately reduce costs for providers. The post Why Innovaccer Is Pouring $250M into Its Agentic AI Platform […]
  • by Frank Vinluan
    Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance. The post Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors appeared first on […]
  • by Austin Speier and Steven Lee
    These products have yet to offer treatment solutions designed to get users from their current health state to a desired future health state. This creates a massive, untapped opening for tools that move people from awareness to action in a clinically meaningful way, without the cost and access barriers of engaging the healthcare system or requiring […]
  • by Angela Adams
    The next wave of radiology AI value will come from closed-loop follow-up. An actionable finding should start a pathway with a measurable end state: the follow-up exam is completed, the referral is completed, or the recommendation is clinically resolved with a documented rationale. The post The Last Mile Problem in AI Radiology: Detection Improves, Follow-Through […]
  • by Katie Adams
    HeartFlow, which makes AI tools to analyze cardiac images, sued its rival Cleerly, alleging infringement on six patents. Cleerly is pushing back. The post Heartflow Sues Cardiac AI Rival Cleerly Over Alleged IP Theft appeared first on MedCity News.
  • by Marissa Plescia
    Vida Health is partnering with ŌURA to use data from the Oura Ring to provide more continuous, personalized cardiometabolic care and improve patient outcomes. The post Vida Health Teams Up with ŌURA to Provide More Personalized Metabolic Care appeared first on MedCity News.
  • by Frank Vinluan
    Travere Therapeutics’ Filspari is now the first FDA-approved drug for focal segmental glomerulosclerosis (FSGS), a rare kidney disease. Analysts project the pill will become a blockbuster seller. The post Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease appeared first on MedCity News.
  • by wlim
    [Sponsored] 74% of healthcare AI is stuck in pilots. The reason isn’t the AI, it’s the data architecture underneath it. Read more to find the solution. The post 5 of the Top 10 U.S. Health Systems Are Moving to This New Health IT Category. Here’s Why. appeared first on MedCity News.
  • by Marie Hattar
    To address the clinical burden and enhance R&D, companies are turning to virtual solutions. This involves synthetic data, digital twin models, and AI to speed analysis. The post Why Synthetic Data is the Antidote to Clinical Trials appeared first on MedCity News.
  • by John Wright
    The question is where will healthcare see the greatest value? Here are five use cases that define the greatest ROI for leveraging agentic AI for clinical supply chain operations. The post Clinical Supply Chain Hits Its AI Turning Point appeared first on MedCity News.